Company Valuation: Allogene Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 2,126 907.1 540.2 446.6 307.9 231.1 - -
Change - -57.34% -40.45% -17.32% -31.06% -24.95% - -
Enterprise Value (EV) 1 1,317 330.6 91.47 234.8 347 -11.03 88.16 -22.83
Change - -74.89% -72.33% 156.69% 47.8% -103.18% 899.42% -125.89%
P/E -7.89x -2.71x -1.54x -1.61x -1.57x -1.1x -1.04x -1.16x
PBR 2.32x 1.36x 1.06x 1.07x 1.07x 0.6x 1.29x 0.55x
PEG - -0.1x 0.16x 0x 0x 0x -0.16x 0.1x
Capitalization / Revenue 55.2x 3,733x 5,686x 20,300x - 61.1x 21.8x 2.91x
EV / Revenue 34.2x 1,361x 963x 10,673x - -2.91x 8.31x -0.29x
EV / EBITDA -5.37x -1.03x -0.29x -0.96x -1.76x 0.05x -0.37x 0.09x
EV / EBIT -5.15x -0.99x -0.28x -0.91x -1.66x 0.05x -0.36x 0.1x
EV / FCF -6.38x -1.46x -0.38x -1.17x -2.32x 0.08x -0.5x 0.15x
FCF Yield -15.7% -68.3% -262% -85.6% -43.1% 1,297% -200% 688%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -1.89 -2.32 -2.09 -1.32 -0.87 -0.604 -0.6424 -0.5742
Distribution rate - - - - - - - -
Net sales 1 38.49 0.243 0.095 0.022 - 3.784 10.61 79.32
EBITDA 1 -245.3 -321.2 -313.5 -243.8 -197 -204 -238.1 -260.3
EBIT 1 -255.8 -335.4 -327.7 -257.5 -209.3 -208 -247 -227
Net income 1 -257 -332.6 -327.3 -257.6 -190.9 -191.3 -230.3 -224.2
Net Debt 1 -809.5 -576.5 -448.7 -211.8 39.16 -242.1 -142.9 -253.9
Reference price 2 14.9200 6.2900 3.2100 2.1300 1.3700 0.6669 0.6669 0.6669
Nbr of stocks (in thousands) 142,516 144,210 168,277 209,672 224,730 346,467 - -
Announcement Date 23/02/22 28/02/23 14/03/24 13/03/25 12/03/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-1.1x-2.91x0.05x-.--% 231M
17.12x6.54x12.53x1.74% 65.42B
31.85x8.5x28.11x0.07% 58.91B
38.62x6.88x20.55x0.84% 55.24B
41.79x5.95x28.33x-.--% 45.66B
32.7x3.15x13.61x-.--% 41.29B
36.32x8.98x23.42x0.36% 36.82B
-18.89x54.48x-20.65x-.--% 34.48B
41.53x8.01x26.87x-.--% 32.5B
-89.49x16.75x-96.22x-.--% 31.69B
Average 13.05x 11.63x 3.66x 0.3% 40B
Weighted average by Cap. 18.86x 11.71x 8.55x 0.44%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Allogene Therapeutics, Inc.

Historical PBR trend

Valuation ratios - PBR - Allogene Therapeutics, Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Allogene Therapeutics, Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Allogene Therapeutics, Inc.


Year-on-year evolution of the Yield

Valuation ratios - Yield - Allogene Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALLO Stock
  4. Valuation Allogene Therapeutics, Inc.